⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

December 22, 2021Clinical Infectious DiseasesOpen Access

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Nct03760146.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Essink et al. (2021) studied this question.

synapsesocial.com/papers/69d90a9a099cd0a57a9f55cd https://doi.org/10.1093/cid/ciab990

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of AgeRCT · 2020 · 152 citations
2Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate VaccineOriginal Research · 2009 · 1,315 citations
3Interim results of an ecological experiment — Conjugate vaccination against the pneumococcus and serotype replacementOriginal Research · 2016 · 132 citations
4Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumoniaCohort Study · 2019 · 80 citations
5Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and MortalityCohort Study · 2014 · 313 citations